公开(公告)号：US20210340152A1

公开(公告)日：2021-11-04

申请号：US17371399

申请日：2021-07-09

Applicant: NOVARTIS AG

Inventor： Ying Huang ,  Bo Liu ,  Liang Mao ,  Long Wang ,  Liladhar Murlidhar Waykole ,  Lijun Zhang

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US11702409B2

公开(公告)日：2023-07-18

申请号：US17125335

申请日：2020-12-17

Applicant: NOVARTIS AG

Inventor： Simona Cotesta ,  Marc Gerspacher ,  Catherine Leblanc ,  Edwige Liliane Jeanne Lorthiois ,  Bo Liu ,  Rainer Machauer ,  Robert Mah ,  Christophe Mura ,  Pascal Rigollier ,  Nadine Schneider ,  Stefan Stutz ,  Andrea Vaupel ,  Nicolas Warin ,  Rainer Wilcken

IPC: C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07B2200/13

Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof;




a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US11091489B2

公开(公告)日：2021-08-17

申请号：US16311638

申请日：2017-06-19

Applicant: NOVARTIS AG

Inventor： Ying Huang ,  Bo Liu ,  Liang Mao ,  Long Wang ,  Liladhar Murlidhar Waykole ,  Lijun Zhang

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02 ,  A61K31/519

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US11548897B2

公开(公告)日：2023-01-10

申请号：US17371399

申请日：2021-07-09

Applicant: NOVARTIS AG

Inventor： Ying Huang ,  Bo Liu ,  Liang Mao ,  Long Wang ,  Liladhar Murlidhar Waykole ,  Lijun Zhang

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02 ,  A61K31/519

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US20220363670A1

公开(公告)日：2022-11-17

申请号：US17125335

申请日：2020-12-17

Applicant: NOVARTIS AG

Inventor： Simona Cotesta ,  Marc Gerspacher ,  Catherine Leblanc ,  Edwige Liliane Jeanne Lorthiois ,  Bo Liu ,  Rainer Machauer ,  Robert Mah ,  Christophe Mura ,  Pascal Rigollier ,  Nadine Schneider ,  Stefan Stutz ,  Andrea Vaupel ,  Nicolas Warin ,  Rainer Wilcken

IPC: C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14 ,  C07D471/04 ,  C07D413/14 ,  C07D487/04

Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.